Results 151 to 160 of about 1,188,382 (179)

Efgartigimod for Guillain-Barré syndrome: a retrospective analysis of efficacy and safety. [PDF]

Ther Adv Neurol Disord
Bi Z, Ye X, Liu P, Lu M, Liu H, Chen M.
europepmc   +1 more source

Guillain-Barré syndrome. [PDF]

BJA Educ
Hunter J, English WA, Wiegers EJA, Jacobs BC.   +3 more
europepmc   +1 more source

Rapid neurological recovery in Guillain-Barré syndrome treated with efgartigimod. [PDF]

Sci Rep
Cheng Y, Li W, Xie S, Guo S, Li C, Zhang M, Wang Y.   +6 more
europepmc   +1 more source

U1 Small Nuclear Ribonucleoprotein Autoantibodies Reflect the Disruption of the Blood-Nerve Barrier in Guillain-Barré Syndrome. [PDF]

Int J Mol Sci
Shimizu F, Koga M, Yamanaka N, Nakamori M.   +3 more
europepmc   +1 more source

Lessons from a Severe Case of Fulminant Guillain-Barré Syndrome: A Case Report. [PDF]

Reports (MDPI)
Saunders JA, Patel SS, Varkey TC, Shaikh S, Conforti A, Murthy G.   +5 more
europepmc   +1 more source

Recurrence of Guillain-Barré Syndrome Is not Uncommon, and a Relapse May Require More Aggressive Treatment than the Original Condition. [PDF]

Clin Pract Cases Emerg Med
Finsterer J.
europepmc   +1 more source

Patient Outcomes Among Medicare Beneficiaries With Guillain-Barré Syndrome. [PDF]

J Peripher Nerv Syst
Wright B, Eiffert SR, Cirincione A, Nardin J, Howard JF, Traub RE.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Association between metabolic syndrome and periodontitis: The role of lipids, inflammatory cytokines, altered host response, and the microbiome

Periodontology 2000, 2021
Suni Travan, Rickard Alexander, J Christopher Fenno   +2 more
exaly